Alpha-1 antitrypsin deficiency (AATD) is a genetic disorder caused by mutations in the SERPINA1 gene, resulting in reduced or dysfunctional alpha-1 antitrypsin (AAT) protein. This deficiency leads to progressive lung and liver diseases, including emphysema, chronic obstructive pulmonary disease, and cirrhosis. Despite its clinical significance, AATD remains underdiagnosed, delaying treatment. This review explores the molecular mechanisms of AATD, emphasizing Z-variant AAT protein accumulation in hepatocytes and excessive protease activity in the lungs. Advancements in imaging modalities – such as computed tomography, magnetic resonance imaging (MRI), dark-field radiography, and hyperpolarized MRI – enhance early diagnosis and disease monitoring. Novel therapies are reshaping AATD management, including small interfering RNA therapies (fazirsiran, belcesiran), gene-editing techniques (CRISPR-Cas9), regenerative approaches, autophagy-enhancing drugs, proteostasis regulators, aerosolized AAT, and artificial intelligence (AI) for real-time disease tracking via wearable devices. The integration of AI, advanced imaging, and emerging therapies represents a paradigm shift in AATD diagnosis and treatment. This review highlights the need for a multidisciplinary approach, early intervention, and personalized medicine to improve outcomes in both pulmonary and hepatic complications.
Background Helicobacter pylori (H. pylori) has been implicated in immune thrombocytopenia (ITP), but the magnitude and reliability of benefit from eradication therapy in randomized trials remain uncertain. Methods We performed a PRISMA-guided, PROSPERO-registered (CRD420251149478) systematic review and meta-analysis restricted to randomized controlled trials (RCTs) comparing H. pylori eradication versus control in ITP. Random-effects models (R) generated risk ratios (RRs) for categorical outcomes—complete response (CR; 8 trials), partial response (PR; 5), overall response (CR + PR; 8), no/minimal response (NR; 8), and 1-year relapse (3)—and mean difference (MD) for platelet count change at ~ 6 months (5). Heterogeneity (I²/τ²), leave-one-out sensitivity, and funnel plots with Egger/Begg tests assessed robustness and small-study effects. Results Eight RCTs (n = 297) across Asia and Latin America met inclusion. Eradication increased CR without statistical significance (RR 1.45, 95% CI 0.87–2.41; I²=40.9%) and did not change PR (RR 0.88, 0.57–1.36; I²=0%) or overall response (RR 1.04, 0.90–1.20; I²=35.9%). NR was significantly lower with eradication (RR 0.65, 0.49–0.85; I²=14.8%). Relapse at 1 year trended lower but was not significant (RR 0.49, 0.24–1.01; I²=0%). Platelet counts rose more after eradication at ~ 6 months (MD + 61.9×10⁹/L, 36.1–87.7; I²=74.9%). Leave-one-out analyses did not alter conclusions. Funnel plots and tests suggested asymmetry for CR and overall response; PR and NR showed no evidence of small-study effects; relapse and platelet change were underpowered for definitive bias testing. Adverse events were mild and infrequently reported; no serious events were attributed to eradication. Conclusions In RCTs, H. pylori eradication for ITP significantly reduces non-response and yields a clinically meaningful platelet rise, while effects on categorical CR/PR and overall response are neutral and relapse reduction is borderline. Given its safety, low cost, and biologic plausibility, testing and offering eradication should be considered early—especially in high-prevalence regions—pending larger multicenter trials to define predictors and durability of benefit.
30 July 2025 in International Journal of STD & AIDS
Syphilitic proctitis is a rare presentation of syphilis that can mimic IBD, posing a diagnostic challenge, especially in immunocompromised patients. We report the case of a 28-year-old transgender woman with a past medical history of ulcerative colitis, HIV, and syphilis, initially misdiagnosed with ulcerative colitis. Sigmoidoscopy showed a rectal ulcer; histology and positive syphilis serologies confirmed syphilitic proctitis. This case highlights the need to consider infectious causes in atypical or treatment-resistant proctitis, emphasising the value of a thorough history and targeted testing.
Background: Myeloproliferative neoplasms (MPN) are an uncommon but important cause of non-cirrhotic portal hypertension (NCPH) and may present with variceal bleeding rather than overt hematologic abnormalities. Diagnosis may be further delayed when polycythemia vera (PV) is masked by iron deficiency or prior venesection, resulting in non-elevated hemoglobin despite an underlying JAK2-positive neoplasm. We report a rare case of isolated gastric variceal bleeding as the presenting manifestation of presinusoidal NCPH in a patient with early myelofibrosis evolving from iron-deficient PV. Case presentation: A 57-year-old man presented with intermittent rectal bleeding and melena. His history was notable for prior erythrocytosis managed with recurrent therapeutic venipunctures and superficial thrombophlebitis. Upper endoscopy revealed isolated gastric varices without esophageal varices. Abdominal computed tomography showed massive splenomegaly with dilated portal and splenic veins, a radiologically normal liver, and no portal or splenic vein thrombosis. Laboratory evaluation showed hemoglobin of 13.2 g/dL and normal liver chemistries. The patient underwent transjugular liver biopsy with concurrent hepatic venous pressure gradient (HVPG) measurement, which demonstrated a normal gradient of 5 mmHg, while histopathology revealed focal hepatic extramedullary erythropoiesis without cirrhosis. JAK2 V617F testing was positive. Peripheral blood smear and bone marrow biopsy showed leukoerythroblastosis, absent iron stores, panmyelosis, atypical megakaryocytic clustering, and grade 1–2 reticulin fibrosis, consistent with early myelofibrosis evolving from iron-deficient polycythemia vera. Conclusions: This case highlights that masked MPN should be considered in patients with non-cirrhotic portal hypertension, massive splenomegaly, or variceal bleeding even when hemoglobin is normal at presentation. Early JAK2 testing and bone marrow evaluation are essential for diagnosis.
Staghorn stones are large branched structures that occupy the renal collecting system, and are usually treated with percutaneous nephrolithotomy (PCNL), this treatment is rarely complicated by extrarenal stone migration, we highlight the diagnostic difficulty in a 36-year-old male that developed extrarenal stone migration and went undiagnosed for 9 months post-PCNL, CT imaging revealed fragments outside the renal collecting system, leading to hydroureteronephrosis and requiring multiple ureteroscopic interventions. We highlight the limitation of x-rays in detecting such complications and emphasize the importance of CT imaging for accurate diagnosis and management, and the role of standardized guidelines in such cases